美国唯一FDA获批开窗腔内移植物应用趋势
研究分析2012年4月至2015年8月美国Zenith开窗腔内移植物(ZFEN)的医生培训与医院订购数据。共553名医生接受培训,388名(70%)订购了2669个装置,月订购量增长911%,月订购医生数增长675%。教学医院占64%订单,但30%培训医生未订购,81%年订购≤5个,提示该技术应用集中度低。
要点
- ZFEN月订购量从2012年6月的9个增至2015年8月的91个,增长911%。
- 553名培训医生中,165名(30%)未订购,272名(81%)年订购≤5个。
- 教学医院占64%订单,最常见设计为2小开窗/1扇贝(55%)。
核心结论
- ZFEN月订购量增长九倍,但医生应用集中度低,仅5%医生订购超过20个,30%未订购。
- 若手术量与结局相关,开窗技术或应考虑区域化至高通量中心。
研究设计与样本
- 回顾性分析2012年4月至2015年8月美国ZFEN订购去标识数据集,包含培训医生数、医生与医院订单及设计配置。
- Cook Medical组装数据集,未参与研究设计、分析或解释。
主要发现
- 553名医生接受培训,388名(70%)订购共2669个装置。
- 月订单量从2012年6月的9个增至2015年8月的91个(增长911%,P < .001)。
- 月订购医生数从8名增至62名(增长675%,P < .001)。
- 教学医院订购1703个(64%),地区分布:中西部927(35%)、南部799(30%)、东北部547(20%)、西部396(15%)。
- 培训医生中165名(30%)未订购,116名(21%)订购1个,144名(26%)订购2-5个,61名(11%)订购6-10个,39名(7%)订购11-20个,28名(5%)订购>20个。
关键数值与推荐
- 有>6个月数据的336名医生中,年均订购3个(标准差4);272名(81%)年订购≤5个,15名(4.5%)年订购11-20个,3名(0.9%)年订购>20个。
- 有设计详情的2618个装置(98%)中,最常见设计为2小开窗/1扇贝(1443个,55%),其次2小开窗/1大开窗(568个,22%)、1小开窗/1扇贝(173个,6.6%)、2小开窗(169个,6.5%)。
- 每个设计平均纳入2.7个靶血管;2071个(79%)纳入三个,398个(15%)纳入两个。
临床怎么用
- 开窗腔内修复技术复杂,应用应集中于有足够手术量的高容量中心以保障结局。
- 培训后未常规开展手术的医生占比较高,需关注技术推广中的质量与准入。
局限性
- 数据来源于厂商订单,非临床结局数据,无法直接评估手术量与并发症的关系。
- 研究仅覆盖2012年4月至2015年8月,不能反映后续应用趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fenestrated endografts are customized, patient-specific, endovascular devices with potential to significantly reduce morbidity and mortality of short-neck infrarenal and juxtarenal abdominal aortic aneurysm repair. The Zenith fenestrated endovascular graft (ZFEN) for abdominal aortic aneurysms (Cook Medical, Bloomington, Ind), Food and Drug Administration-approved in 2012, remains the only fenestrated device available in the United States. This technology is among the most technically complex catheter-based procedures and, therefore, inherently associated with serious risk for device-related complications. We sought to define patterns of physician and hospital adoption of ZFEN. METHODS: Deidentified datasets containing numbers of physicians trained, orders by physicians and hospitals, and designs (fenestration/scallop configuration) was provided for U.S. ZFEN devices ordered (April 2012-August 2015). We evaluated the number of physicians trained, the number of devices ordered, hospital characteristics, and fenestration/scallop design configurations. Cook Medical assembled the datasets but played no role in study design, analysis, or interpretation of data. RESULTS: Between April 2012 and August 2015, 553 physicians attended formal ZFEN training sessions, 388 (70%) of whom ordered a total of 2669 devices. An increase in orders per month (nine in June 2012 and 91 in August 2015, 911% growth; P < .001) and in number of physicians ordering per month (eight in June 2012 and 62 in August 2015, 675% growth; P < .001) was observed. Teaching hospitals, representing all U.S. regions (Midwest 927, 35%; South 799, 30%; Northeast 547, 20%; West 396, 15%), accounted for 1703 (64%) ZFEN orders. Of 553 trained physicians, 165 (30%) ordered no devices, 116 (21%) ordered 1 device, 144 (26%) ordered 2-5 devices, 61 (11%) ordered 6-10 devices, 39 (7%) ordered 11-20, and 28 (5%) ordered >20 devices. For physicians contributing >6 months of data (n = 336), the average number of devices ordered per year was three (standard deviation, 4); 272 (81%) ordered ≤ 5 devices/year, 15 (4.5%) ordered 11-20 devices/year, and 3 (0.9%) ordered >20 devices/year. Of devices with design details available (2618 of 2669; 98%), most common designs were 2 small fenestrations/1 scallop (1443; 55%), 2 small fenestrations/1 large fenestration (568; 22%), 1 small fenestration/1 scallop (173, 6.6%), and 2 small fenestrations (169; 6.5%). The average number of target vessels incorporated in each design was 2.7/device; 2071 (79%) incorporated three, 398 (15%) incorporated two. CONCLUSIONS: Since 2012, ZFEN has demonstrated a ninefold increase in monthly orders, with 553 physicians trained. Unlike the experience of rapid dissemination seen with infrarenal endografts, only 28 (5%) physicians have ordered >20, whereas 165 (30%) have ordered none, and 272 (81%) ordered ≤ 5 devices/year. Assuming that volume, in general, correlates with outcomes, this adoption pattern raises questions whether fenestrated technology should be regionalized to high-volume centers.
引用
- Simons JP, Shue B, Flahive JM, et al. Trends in use of the only Food and Drug Administration-approved commercially available fenestrated endovascular aneurysm repair device in the United States. J Vasc Surg. 2017. PMID: 28254395. doi:10.1016/j.jvs.2016.10.101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。